Get the Stockscreener App
8.55
6.15%
-0.56
After Hours:
8.55
Bridgebio Oncology Therapeutics Inc stock is traded at $8.55, with a volume of 747.18K.
It is down -6.15% in the last 24 hours and down -3.61% over the past month.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
See More
Previous Close:
$9.11
Open:
$9.02
24h Volume:
747.18K
Relative Volume:
2.21
Market Cap:
$684.92M
Revenue:
-
Net Income/Loss:
$-83.12M
P/E Ratio:
-5.7164
EPS:
-1.4957
Net Cash Flow:
$-114.50M
1W Performance:
+0.47%
1M Performance:
-3.61%
6M Performance:
-30.99%
1Y Performance:
+0.00%
1-Day Range:
$8.40
$9.25
1-Week Range:
$8.16
$9.26
52-Week Range:
$7.60
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Name
Bridgebio Oncology Therapeutics Inc
Sector
Industry
Phone
857 702 0377
Address
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
8.55 | 729.78M | 0 | -83.12M | -114.50M | -1.4957 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | Raymond James | Outperform |
| Dec-05-25 | Initiated | Morgan Stanley | Overweight |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Piper Sandler | Overweight |
View All
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Latest News
BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Stem Stock SlideProfit Announcement - Newser
BBOT Dips Close to Lows With One Cancer Drug Update Steering Trade - Bez Kabli
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks - TipRanks
BridgeBio Oncology Therapeutics (BBOT) registers 63.05M shares for resale — supplement adds Q1 2026 10-Q - Stock Titan
BridgeBio Oncology Therapeutics, Inc.Common Stock (Nasdaq:BBOT) Stock Quote - FinancialContent
BridgeBio Oncology Therapeutics (BBOT) Reports Q1 2026 Results: Positive RAS-Pathway Cancer Drug Data, Cash Runway Into 2028 - Minichart
BridgeBio Oncology as of March 31 Cash, Cash Equivalents and Marketable Securities Totaling $388.9M >BBOT - Moomoo
BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bbot reports first quarter 2026 financial results and update on corporate progress - marketscreener.com
BridgeBio Oncology Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
BridgeBio Oncology Therapeutics 1Q 2026: Net loss $(42.1M), EPS $(526.11) — 10-Q Summary - TradingView
[10-Q] BridgeBio Oncology Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BridgeBio Oncology (Nasdaq: BBOT) widens Q1 2026 loss while advancing RAS-pathway cancer programs - Stock Titan
BridgeBio Oncology Thera 1Q Loss/Shr $526.11 >BBOT - Moomoo
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress - GlobeNewswire
Cancer drug trials show tumor shrinkage as BBOT funds work into 2028 - Stock Titan
BridgeBio Oncology (BBOT) grants COO 758,222 stock options - Stock Titan
BridgeBio Oncology CEO granted 1,103,837 options | BBOT Insider Trading - Stock Titan
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
This Arxis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
A Quick Look at Today's Ratings for BridgeBio Oncology Therapeutics(BBOT.US), With a Forecast Between $21 to $41 - Moomoo
BridgeBio Oncology Price Target Announced at $23.00/Share by Canaccord Genuity - Moomoo
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week LowTime to Sell? - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) officer has 1,047 shares withheld for RSU tax - Stock Titan
BridgeBio Oncology (BBOT) CEO has RSU shares withheld to cover taxes - Stock Titan
Tax withholding trims BridgeBio Oncology (BBOT) insider holdings slightly - Stock Titan
[EFFECT] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price Today & Analysis - Gotrade
BBOT (NASDAQ: BBOT) registers 63.05M common shares for resale - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) accounting chief reports initial equity stake - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) COO Idan details initial stock and option holdings - Stock Titan
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
63.05M shares registered; CEO change and consulting deal at BridgeBio Oncology (BBOT) - Stock Titan
Ex-CEO Wallace stays advisor at BridgeBio Oncology (BBOT) - Stock Titan
[ARS] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
BridgeBio Oncology Therapeutics appoints new CEO and COO - MSN
BridgeBio Oncology (BBOT) Stock News, Page 3 - Stock Titan
BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset - MSN
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy - Investing.com
Stifel Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
BridgeBio (BBOT) Stock: Price Pattern Formation | Q4 2025: EPS Beats ForecastsDividend Growth Rate - Xã Thanh Hà
BridgeBio Oncology Overhauls Leadership for Next Development Phase - TipRanks
BridgeBio Oncology names Pedro Beltran as new CEO By Investing.com - Investing.com India
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):